Legend Biotech (LEGN) stock fell 7.52% in premarket trading Thursday after the cell therapy company announced an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million. The decline comes despite the company's strong market position and analyst Buy rating with a $58.57 price target, though recent earnings showed a wider-than-expected loss and revenue slightly below consensus.

Legend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million in gross proceeds. The offering is expected to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.

Legend Biotech (LEGN) surged 18% on Monday following bullish analyst updates from H.C. Wainwright and RBC Capital. The rally was partly inspired by Eli Lilly's $7 billion acquisition of Kelonia Therapeutics, a CAR-T therapy developer similar to Legend. Analysts highlighted Legend's promising pipeline programs, including encouraging progress on its CD19/CD20 dual-targeted therapy.

Suvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk management decision following the dramatic stock appreciation rather than a loss of conviction in the company's fundamentals.

A study of CARVYKTI® demonstrated lasting treatment-free remissions in 80% of standard-risk multiple myeloma patients when used as early as second-line therapy, with improved immune fitness potentially correlating with longer progression-free survival.

Legend Biotech was awarded Foreign Investor of the Year at the 2025 Flanders International Business Awards for its €165 million investment with Johnson & Johnson to expand cell therapy manufacturing in Ghent, Belgium, growing from 2 to over 1,000 employees.

The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.

Legend Biotech reported strong Q1 2025 results, with CARVYKTI® net trade sales of $369 million and over 6,000 patients treated to date. The company received positive regulatory updates, expanded manufacturing capacity, and maintained a strong cash position of $1 billion, which is expected to provide financial runway into Q2 2026.

The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.

The global gene therapy market is expected to grow significantly, driven by technological advancements, increased R&D investment, and the rising prevalence of genetic disorders. Key players in the market are focusing on developing transformative gene therapy platforms and expanding their capabilities through strategic collaborations and acquisitions.

Legend Biotech, a global leader in cell therapy, will host a conference call on August 9, 2024, to review its second-quarter 2024 results. The company is developing advanced cell therapies across various technology platforms.